Table 2B.
Overview inflammatory biomarkers significantly associated with baseline clinical scores in MS publications.
| Biomarker | Study | Quality | Cohort (n) | Age (y) | EDSS | Clinical measure | Correlation coefficient |
|---|---|---|---|---|---|---|---|
| 15(S)-PGF2α / 20:4 µg | Lam, 2016 | L | RRMS (23) SPMS (24) PPMS (15) |
35.9 49.4 55 |
1.5 5.8 4.0 |
EDSS (RR + SP + PP) |
0.313 |
| 15(S)-PGF2α / CSF µg | Lam, 2016 | L | RRMS (23) SPMS (24) PPMS (15) |
35.9 49.4 55 |
1.5 5.8 4.0 |
EDSS (RR + SP + PP) |
0.280 |
| Anti-NF-L antibodies | Ehling, 2004 | L | MS (130) | 42.1 | 3.7 | EDSS | NR |
| Silber, 2002 | L | RRMS (38) SPMS (18) PPMS (10) |
29 28 41 |
NR NR NR |
EDSS (RR + SP + PP: n = 49) |
0.620 | |
| Anti-NF-H antibodies | Silber, 2002 | L | RRMS (38) SPMS (18) PPMS (10) |
29 28 41 |
NR NR NR |
EDSS (RR + SP + PP: n = 49) |
0.510 |
| Anti-tubulin antibodies | Silber, 2002 | L | RRMS (38) SPMS (18) PPMS (10) |
29 28 41 |
NR NR NR |
EDSS (RR + SP + PP: n = 49) |
0.340 |
| B-cell / monocyte ratio | Cepok, 2001 | L | RRMS (21) SPMS (6) PPMS (4) | NR NR NR |
NR NR NR |
EDSS (RR + SP + PP) |
NR |
| PI (RR + SP + PP) |
0.570 | ||||||
| PI (RR + SP) |
0.590 | ||||||
| PI (RR) |
0.630 | ||||||
| YKL-40 (CHI3L1) | Huss, 20 20 | M | RRMS (47) PMS (39) |
34 53 |
2.0 6.0 |
EDSS (RR) |
0.140 |
| EDSS (P) |
-0.050 | ||||||
| Gil-Perotin, 2019 | M | RRMS (99) SPMS (35) PPMS (23) |
35 45 51 |
2.0 5.5 5.0 |
EDSS (RR + SP + PP) |
0.210 | |
| Novakova, 2017 | M | RRMS (59) | 37 | 2.5 | EDSS | 0.274 | |
| MSSS | 0.297 | ||||||
| Complement factor C3 | Aeinehband, 2017 | L | MS (48) | 41.2 | 3.0 | EDSS | 0.170 |
| MSSS | 0.130 | ||||||
| Sladkova, 2011 | L | CIS (20) | 34.9 | NR | EDSS | NR | |
| GFAP | Azzolini, 2022 | M | RRMS (51) | 36.5 | 1.5 | EDSS | NR |
| BREMS | 0.501 | ||||||
| Abdelhak, 2018 | H | RRMS+ (24) RRMS- (18) SPMS (13) PPMS (25) |
36 28 50 53 |
2.3 2.0 6.5 4.5 |
EDSS (RR + SP + PP) |
0.400 | |
| EDSS (RR) |
NR | ||||||
| EDSS (SP+PP) |
NR | ||||||
| Novakova, 2017 | M | RRMS (59) | 37 | 2.5 | EDSS | NR | |
| MSSS | NR | ||||||
| IgG oligoclonal bands (OCB) | Sladkova, 2011 | L | CIS (20) | 34.9 | NR | EDSS | “positive” |
| miR-142-3p | De Vito, 2021 | M | MS (151) | 39.5 | 2.0 | EDSS | NR |
| PI | 0.270 | ||||||
| sBCMA + IgG + IgG index | Milstein, 2019 | L | RRMS (118) PMS (173) |
42.3 55.3 |
NR NR |
MSSS (RR + P: n = 191) |
0.240 |
| MSSS (RR: n = 71) |
0.190 | ||||||
| MSSS (P: n = 120) |
0.260 | ||||||
| ARMSS (RR + P: n = 190) |
0.220 | ||||||
| ARMSS (RR: n = 70) |
0.080 | ||||||
| ARMSS (P: n = 120) |
0.250 | ||||||
| MS-DSS (RR + P: n = 244) |
0.230 | ||||||
| MS-DSS (RR: n = 98) |
0.070 | ||||||
| MS-DSS (P: n = 146) |
0.240 | ||||||
| sCD14 + sCD163 + YKL-40 | Milstein, 2019 | L | RRMS (118) PMS (173) |
42.3 55.3 |
NR NR |
MSSS (RR + P: n = 171) |
0.150 |
| ARMSS (RR + P: n = 170) |
0.220 | ||||||
| MS-DSS (RR + P: n = 211) |
0.180 | ||||||
| sCD27 | Milstein, 2019 | L | RRMS (118) PMS (173) |
42.3 55.3 |
NR NR |
MSSS (RR + P: n = 171) |
0.180 |
| MSSS (RR: n = 63) |
0.200 | ||||||
| MSSS (P: n = 108) |
0.230 | ||||||
| MS-DSS (RR + P: n = 210) |
0.200 | ||||||
| MS-DSS (RR: n = 86) |
0.060 | ||||||
| MS-DSS (P: n = 124) |
0.240 | ||||||
| TNF-α | Stampanoni-Bassi, 2018 | L | RRMS (205) | 34.8 | 1.5 | EDSS | NR |
| Malekzadeh, 2017 | L | RRMS (23) SPMS (22) PPMS (11) |
45.2 (MS) | 2.0 5.6 5.0 |
EDSS (RR + SP + PP) |
NR | |
| FSS (RR + SP + PP) |
NR | ||||||
| Obradovic, 2012 | L | MS (60) | 43.5 | 3.8 | EDSS | NR | |
| Sharief, 1991 | L | PPMS (32) | 37.4 | 3.7 | EDSS (n = 17) |
0.834 | |
| PI (n = 17) |
0.741 |
ARMSS, Age-Related Multiple Sclerosis Severity; BREMS, Bayesian Risk Estimate for Multiple Sclerosis; CIS, Clinically Isolated Syndrome; EDSS, Expanded Disability Status Scale; FSS, Fatigue Severity Scale; H, High quality; L, Low quality; M, Moderate quality; MS, Multiple Sclerosis; MS-DSS, Multiple Sclerosis Disease Severity Scale; MSSS, Multiple Sclerosis Severity Score; NR, not reported; PI, Progression Index; P(MS), Progressive Multiple Sclerosis; PP(MS), Primary Progressive Multiple Sclerosis; RR(MS), Relapsing-remitting Multiple Sclerosis; RR(MS)+, acute exacerbation; RR(MS)-, remission; SP(MS), Secondary Progressive Multiple Sclerosis. Significant p-values are marked in bold.